Adenoviruses have been studied intensively for over 50 years as models of virus–cell
interactions and latterly as gene vectors. With the advent of more sophisticated structural …

Oncolytic viruses (OVs) are emerging cancer therapeutics that offer a multifaceted
therapeutic platform for the benefits of replicating and lysing tumor cells, being engineered …

Abstract Interleukin-12 (IL-12) has emerged as one of the most potent agents for anti-tumor
immunotherapy. However, potentially lethal toxicity associated with systemic administration …

Immune checkpoint inhibitors, including anti-programmed cell death 1 (PD-1) antibody,
provide improved clinical outcome in certain cancers. However, pancreatic ductal …

Augmenting antitumor immunity is a promising way to enhance the potency of oncolytic
adenoviral therapy. Granulocyte–macrophage colony–stimulating factor (GMCSF) can …

Granulocyte macrophage colony-stimulating factor (GMCSF) can mediate antitumor effects
by recruiting natural killer cells and by induction of tumor-specific cytotoxic T-cells through …

Adoptive cell therapy holds much promise in the treatment of cancer but results in solid
tumors have been modest. The notable exception is tumor-infiltrating lymphocyte (TIL) …

Oncolytic viruses (OVs) are unique anticancer agents based on their pleotropic modes of
action, which include, besides viral tumor cell lysis, activation of antitumor immunity. A panel …

Cancer-specificity is the key requirement for a drug or treatment regimen to be effective
against malignant disease—and has rarely been achieved adequately to date. Therefore …

Purpose: Tumor targeting upon intravenous administration and subsequent intratumoral
virus dissemination are key features to improve oncolytic adenovirus therapy. VCN-01 is a …